Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03964922

Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation — EVADE  

Allogeneic Stem Cell Transplantation Clinical Trial

Official title:
Study of the Immunoevasive Mecanisms and Especially Myeloid Suppressive Cells in the Medullar Microenvironment Employed by Myeloid Malignancy (AML and High Risk MDS) When Relapsing After Allogeneic Stem Cell Transplantation

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the only treatment available to cure acute myeloid leukemia and high risk myelodysplasia. Allo-HSCT has an anti-tumor effect (called the graft versus leukemia effect= GVL) mediated by donor lymphocytes. This GVL effect is often associated with graft-versus-host disease (GVHD). Several studies have shown that the relapse incidence is lower in patients developing chronic GVHD. These studies confirm the impact of donor immune system on leukemic residual cells. In fact, the relapse incidence increased in patients with no sign of GVHD. The investigators assume that leukemic cells probably use mechanisms to inhibit the allogeneic response. These escape mechanisms to immunosurveillance have been described in other malignancies. Out of context of the allo-HSCT, in acute myeloid leukemias and myelodysplasia, correlations between the severity of the disease and the presence of regulatory T cells (Tregs) or exhausted T cells (PD1 positive) in the bone marrow and in the blood of patients were described at the time of diagnosis or relapse. Myeloid Derived Suppressive Cells (MDSCs) have been described as capable of inducing Tregs and exhausted T cells in the tumor microenvironment.The investigators want to evaluate the role of myeloid suppressive cells in bone marrow after allo HSCT. They hypothesize that their presence in bone marrow and / or blood recipient is correlated to the relapse incidence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03964922
Study type Interventional
Source Central Hospital, Nancy, France
Contact Maud D'AVENI, MD
Phone +33383153289
Email m.daveni-piney@chru-nancy.fr
Status Not yet recruiting
Phase N/A
Start date September 1, 2019
Completion date November 1, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Terminated NCT01185223 - Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation Phase 3
Not yet recruiting NCT01212796 - Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH N/A
Terminated NCT00737113 - Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Completed NCT02273024 - Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation N/A
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Completed NCT01092026 - Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00883714 - Exercise During the Allogeneic Stem Cell Transplantation Phase 3
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT06256341 - HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Completed NCT05088941 - Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Recruiting NCT02533947 - Cognition in Allogeneic Stem Cell Transplanted Patients and Sports N/A
Completed NCT01560689 - Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06297629 - A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation Phase 2
Completed NCT01929980 - Bortezomib to Treat Significant Complication of HSCT Phase 2
Recruiting NCT01166009 - CIBMTR Research Database